Princeton Junction, NJ, United States of America

Wenxue Wu

This inventor holds 30 USPTO granted patents and 7 published patent applications, plus 4 CIPO patents and 16 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Lexicon Pharmaceuticals, Inc., Schering Corporation. Active years: 2003-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Wenxue Wu. Retrieved from https://idiyas.com/inventor/wenxue-wu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 30 (Patent Applications = 7)

% Patents Active = 73.3

CIPO Patents = 4 (Patent Applications = 1)

EPO Patents = 16 (Patent Applications = 16)

Average Co-Inventor Count = 4.8

ph-index = 4

Forward Citations = 70(Granted Patents)

Location History:

Princeton Jct, NJ (US) (2003)
West Windsor, NJ (US) (2010)
Princeton, NJ (US) (2010 - 2012)
Princeton Junction, NJ (US) (2005 - 2021)

Company Filing History:

17 out of 89

Lexicon Pharmaceuticals, Inc.

Years Active: 2003-2025

Loading Chart...

Areas of Expertise:

AAK1 Inhibitors

Tryptophan Hydroxylase Inhibitors

Thrombin Receptor Antagonists

Imidazole-Based Compounds

Piperazine Compounds

PDE IV Inhibitors

Sodium Glucose Co-Transporter

Stereoselective Alkylation

Crystalline Polymorphs

Pharmaceutical Salts

Synthesis Methods

Himbacine Analogs

30 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12344596 - Solid forms of (S)-1-((2',6-bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine and salts thereof (2025-07-01),

2. 12312325 - Methods and compounds useful in the synthesis of an AAK1 inhibitor (2025-05-27),

3. 10968192 - Crystalline solid forms of N-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oxopropan-2-yl)-4-(4-(2-methyl-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)butanamide and methods of their synthesis (2021-04-06),

4. 8658682 - (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone dihydrate and methods of its use (2014-02-25),

5. 8629156 - Tryptophan hydroxylase inhibitors (2014-01-14),

6. 8575362 - Methods of preparing 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds (2013-11-05),

7. 8450532 - Compounds useful in the preparation of tryptophan hydroxylase inhibitors (2013-05-28),

8. 8293878 - Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors (2012-10-23),

9. 8093280 - Methods of preparing imidazole-based compounds (2012-01-10),

10. 8026347 - Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors (2011-09-27),

11. 7968729 - 1-phenyl-1H-pyrazole-based compounds (2011-06-28),

12. 7968726 - Methods of preparing imidazole-based bicyclic compounds (2011-06-28),

13. 7951941 - Process for preparing 5-alkyl-7H-pyrrolo[2,3-d] pyrimindine-2-ols (2011-05-31),

14. 7919618 - Synthesis of piperazines, piperidines and related compounds (2011-04-05),

15. 7897763 - Process for the preparation of substituted phenylalanines (2011-03-01),

Title: Wenxue Wu: A Pioneer in Pharmaceutical Innovations

Introduction

Wenxue Wu, based in Princeton Junction, NJ, has made substantial contributions to the field of pharmaceuticals with an impressive portfolio of 28 patents. His innovative approaches to drug formulation and synthesis have led to significant advancements in medicinal chemistry.

Latest Patents

Wu's latest patents focus on intricate chemical compounds and their solid forms. Notably, he has developed crystalline solid forms of N-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oxopropan-2-yl)-4-(4-(2-methyl-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)butanamide, along with methods of their synthesis. Additionally, he has patented methods of preparing (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone dihydrate and its applications.

Career Highlights

Wenxue Wu has worked with prominent companies in the pharmaceutical industry, including Lexicon Pharmaceuticals, Inc. and Schering Corporation. His expertise and innovative thinking have been instrumental in driving forward various research initiatives.

Collaborations

Throughout his career, Wu has collaborated with notable professionals such as Haiming Zhang and Ramanaiah C Kanamarlapudi. These partnerships have fostered a collaborative research environment conducive to cutting-edge developments.

Conclusion

Wenxue Wu's commitment to innovation within the pharmaceutical realm is evident through his numerous patents and collaborations. His work continues to pave the way for advancements in drug development, showcasing the importance of creativity and teamwork in science.

Profile summary based on public USPTO records.